Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.
Many recombinant poxviral vaccines are currently in clinical trials for cancer and infectious diseases. However, these agents have failed to generate T cell responses specific for recombinant gene products at levels comparable with T cell responses associated with natural viral infections. The recen...
| Main Authors: | , , , , , , , , |
|---|---|
| Formato: | Journal article |
| Idioma: | English |
| Publicado em: |
2005
|
| _version_ | 1826256981124448256 |
|---|---|
| author | Smith, C Mirza, F Pasquetto, V Tscharke, D Palmowski, M Dunbar, P Sette, A Harris, A Cerundolo, V |
| author_facet | Smith, C Mirza, F Pasquetto, V Tscharke, D Palmowski, M Dunbar, P Sette, A Harris, A Cerundolo, V |
| author_sort | Smith, C |
| collection | OXFORD |
| description | Many recombinant poxviral vaccines are currently in clinical trials for cancer and infectious diseases. However, these agents have failed to generate T cell responses specific for recombinant gene products at levels comparable with T cell responses associated with natural viral infections. The recent identification of vaccinia-encoded CTL epitopes, including a new epitope described in this study, allows the simultaneous comparison of CTL responses specific for poxviral and recombinant epitopes. We performed detailed kinetic analyses of CTL responses in HLA-A*0201 patients receiving repeated injections of recombinant modified vaccinia Ankara encoding a string of melanoma tumor Ag epitopes. The vaccine-driven CTL hierarchy was dominated by modified vaccinia Ankara epitope-specific responses, even in patients who had not received previous smallpox vaccination. The only recombinant epitope that was able to impact on the CTL hierarchy was the melan-A26-35 analog epitope, whereas responses specific for the weaker affinity epitope NY-ESO-1(157-165) failed to be expanded above the level detected in prevaccination samples. Our results demonstrate that immunodominant vaccinia-specific CTL responses limit the effectiveness of poxviruses in recombinant vaccination strategies and that more powerful priming strategies are required to overcome immunodominance of poxvirus-specific T cell responses. |
| first_indexed | 2024-03-06T18:10:54Z |
| format | Journal article |
| id | oxford-uuid:02fbe9f6-a7ea-4e2f-b65f-c85d1b3b7564 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:10:54Z |
| publishDate | 2005 |
| record_format | dspace |
| spelling | oxford-uuid:02fbe9f6-a7ea-4e2f-b65f-c85d1b3b75642022-03-26T08:43:42ZImmunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:02fbe9f6-a7ea-4e2f-b65f-c85d1b3b7564EnglishSymplectic Elements at Oxford2005Smith, CMirza, FPasquetto, VTscharke, DPalmowski, MDunbar, PSette, AHarris, ACerundolo, VMany recombinant poxviral vaccines are currently in clinical trials for cancer and infectious diseases. However, these agents have failed to generate T cell responses specific for recombinant gene products at levels comparable with T cell responses associated with natural viral infections. The recent identification of vaccinia-encoded CTL epitopes, including a new epitope described in this study, allows the simultaneous comparison of CTL responses specific for poxviral and recombinant epitopes. We performed detailed kinetic analyses of CTL responses in HLA-A*0201 patients receiving repeated injections of recombinant modified vaccinia Ankara encoding a string of melanoma tumor Ag epitopes. The vaccine-driven CTL hierarchy was dominated by modified vaccinia Ankara epitope-specific responses, even in patients who had not received previous smallpox vaccination. The only recombinant epitope that was able to impact on the CTL hierarchy was the melan-A26-35 analog epitope, whereas responses specific for the weaker affinity epitope NY-ESO-1(157-165) failed to be expanded above the level detected in prevaccination samples. Our results demonstrate that immunodominant vaccinia-specific CTL responses limit the effectiveness of poxviruses in recombinant vaccination strategies and that more powerful priming strategies are required to overcome immunodominance of poxvirus-specific T cell responses. |
| spellingShingle | Smith, C Mirza, F Pasquetto, V Tscharke, D Palmowski, M Dunbar, P Sette, A Harris, A Cerundolo, V Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. |
| title | Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. |
| title_full | Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. |
| title_fullStr | Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. |
| title_full_unstemmed | Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. |
| title_short | Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. |
| title_sort | immunodominance of poxviral specific ctl in a human trial of recombinant modified vaccinia ankara |
| work_keys_str_mv | AT smithc immunodominanceofpoxviralspecificctlinahumantrialofrecombinantmodifiedvacciniaankara AT mirzaf immunodominanceofpoxviralspecificctlinahumantrialofrecombinantmodifiedvacciniaankara AT pasquettov immunodominanceofpoxviralspecificctlinahumantrialofrecombinantmodifiedvacciniaankara AT tscharked immunodominanceofpoxviralspecificctlinahumantrialofrecombinantmodifiedvacciniaankara AT palmowskim immunodominanceofpoxviralspecificctlinahumantrialofrecombinantmodifiedvacciniaankara AT dunbarp immunodominanceofpoxviralspecificctlinahumantrialofrecombinantmodifiedvacciniaankara AT settea immunodominanceofpoxviralspecificctlinahumantrialofrecombinantmodifiedvacciniaankara AT harrisa immunodominanceofpoxviralspecificctlinahumantrialofrecombinantmodifiedvacciniaankara AT cerundolov immunodominanceofpoxviralspecificctlinahumantrialofrecombinantmodifiedvacciniaankara |